Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Vedotin + Osimertinib vs Chemo in c-Met+ EGFR-mutant NSCLC
NCT06093503Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 3 trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc.. Planned start May 2024; status: withdrawn.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06093503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093503.